Table of Contents
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra. The management of Parkinson’s symptoms primarily involves medications that aim to restore dopamine levels or mimic its action in the brain. Understanding the mechanisms of these medications is essential for effective treatment planning.
Primary Classes of Parkinson’s Medications
- Levodopa and Dopamine Agonists
- MAO-B Inhibitors
- COMT Inhibitors
- Anticholinergic Agents
- Other Adjunct Medications
Levodopa and Dopamine Agonists
Levodopa, the precursor to dopamine, crosses the blood-brain barrier and is converted into dopamine in the brain, directly replenishing dopamine levels. Dopamine agonists, such as pramipexole and ropinirole, bind directly to dopamine receptors, mimicking dopamine’s effects without requiring conversion.
Mechanism of Levodopa
Levodopa is transported into the brain via active transport and converted to dopamine by the enzyme aromatic L-amino acid decarboxylase. This increase in dopamine alleviates motor symptoms like bradykinesia, rigidity, and tremors.
Mechanism of Dopamine Agonists
Dopamine agonists directly stimulate dopamine receptors, primarily D2-like receptors, to produce symptomatic relief. They are often used in early stages or as adjuncts to levodopa therapy.
MAO-B and COMT Inhibitors
These medications prolong the action of dopamine in the brain by inhibiting its breakdown. They are used to enhance and extend the effects of levodopa therapy.
MAO-B Inhibitors
Selegiline and rasagiline selectively inhibit monoamine oxidase B (MAO-B), the enzyme responsible for dopamine degradation. This results in increased dopamine availability and reduced motor fluctuations.
COMT Inhibitors
Entacapone and tolcapone inhibit catechol-O-methyltransferase (COMT), an enzyme that metabolizes levodopa. By blocking COMT, these drugs increase levodopa’s half-life and brain availability.
Anticholinergic Agents
Anticholinergic drugs like benztropine and trihexyphenidyl reduce acetylcholine activity in the basal ganglia. This helps rebalance neurotransmitter activity and alleviates tremors, especially in younger patients.
Other Adjunct Medications
Additional medications include amantadine, which has dopaminergic and NMDA receptor antagonist properties, and is used for dyskinesias. Deep brain stimulation and other surgical options are considered when medication effects diminish.